Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.
Bristol-Myers Squibb has swooped in with $60 million upfront to gain an option on Bavarian Nordic's Phase III therapeutic prostate cancer vaccine Prostvac, ready to shell out an additional $915 million-plus in milestones if it takes the next step to license and ultimately commercialize the therapy.
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
Prostate cancer could affect as many as one in 6 men during their lifetime, according to the U.S. National Cancer Institute, and for some their cancers recur and become hormone-resistant. The Cancer Institute of New Jersey and the National Cancer Institute have hooked up to see if combining a vaccine and hormone treatment will improve the response.
Sometimes, the sum of the parts is greater than the whole, and this can be true for cancer therapies as well. Researchers are hoping that combining Prostvac, the investigational therapeutic cancer...
Danish biotech Bavarian Nordic saw its stock shoot up after the FDA approved a Phase III trial design for Prostvac, the company's prostate cancer vaccine. The company's stock rose as much as 6.5
Shares of Bavarian Nordic jumped seven percent after the Danish drug developer asserted that it is close to landing a big pharma partner for its closely watched prostate cancer vaccine, which is